A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Angiopoietic factors and retinopathy in pregnancies complicated with Type 1 diabetes
Tekijät: Loukovaara S, Immonen I, Koistinen R, Rudge J, Teramo KA, Laatikainen L, Hiilesmaa V, Kaaja RJ
Julkaisuvuosi: 2004
Journal: Diabetic Medicine
Tietokannassa oleva lehden nimi: Diabetic medicine : a journal of the British Diabetic Association
Lehden akronyymi: Diabet Med
Vuosikerta: 21
Numero: 7
Aloitussivu: 697
Lopetussivu: 704
Sivujen määrä: 8
ISSN: 0742-3071
DOI: https://doi.org/10.1111/j.1464-5491.2004.01235.x
Tiivistelmä
To evaluate the role of systemic angiopoietic factors in the progression of diabetic retinopathy during pregnancy.\nIn a prospective study of 26 pregnant women with diabetes and eight non-diabetic pregnant women, retinopathy was graded from fundus photographs. Plasma levels of angiopoietin-1, angiopoietin-2, human vascular endothelial growth factor A (hVEGF-A), and total soluble receptor of vascular endothelial growth factor (sVEGF) receptor-1 were measured during the first and third trimester and 3 months postpartum.\nIn diabetic women, levels of angiopoietin-2 were 26.5 ng/ml (12.1-47.7) (median and range) during the first trimester, 2.9 ng/ml (0.6-3.5) during the third trimester, and 0.5 ng/ml (0.3-0.7) 3 months postpartum, compared with 44.3 (38.3-61.9), 5.7 (3.1-8.4) and 0.9 (0.6-4.9) ng/ml, respectively, in non-diabetic women (P = 0.002 between groups). Levels of angiopoietin-1 and sVEGF receptor-1 did not differ between the groups. Postpartum hVEGF-A levels were lowest in women with progression of retinopathy. In logistic regression analyses, progression of retinopathy during pregnancy was not explained by the levels of the angiopoietic factors.\nThe circulating levels of angiopoietic factors in pregnant diabetic women were either lower than (Ang-2) or similar to (Ang-1, hVEGF-A, VEGFR-1) those levels observed in non-diabetic pregnant women. The levels of angiopoietic factors measured here appear not to be connected with the progression of retinopathy during pregnancy.\nAIMS\nMETHODS\nRESULTS\nCONCLUSIONS
To evaluate the role of systemic angiopoietic factors in the progression of diabetic retinopathy during pregnancy.\nIn a prospective study of 26 pregnant women with diabetes and eight non-diabetic pregnant women, retinopathy was graded from fundus photographs. Plasma levels of angiopoietin-1, angiopoietin-2, human vascular endothelial growth factor A (hVEGF-A), and total soluble receptor of vascular endothelial growth factor (sVEGF) receptor-1 were measured during the first and third trimester and 3 months postpartum.\nIn diabetic women, levels of angiopoietin-2 were 26.5 ng/ml (12.1-47.7) (median and range) during the first trimester, 2.9 ng/ml (0.6-3.5) during the third trimester, and 0.5 ng/ml (0.3-0.7) 3 months postpartum, compared with 44.3 (38.3-61.9), 5.7 (3.1-8.4) and 0.9 (0.6-4.9) ng/ml, respectively, in non-diabetic women (P = 0.002 between groups). Levels of angiopoietin-1 and sVEGF receptor-1 did not differ between the groups. Postpartum hVEGF-A levels were lowest in women with progression of retinopathy. In logistic regression analyses, progression of retinopathy during pregnancy was not explained by the levels of the angiopoietic factors.\nThe circulating levels of angiopoietic factors in pregnant diabetic women were either lower than (Ang-2) or similar to (Ang-1, hVEGF-A, VEGFR-1) those levels observed in non-diabetic pregnant women. The levels of angiopoietic factors measured here appear not to be connected with the progression of retinopathy during pregnancy.\nAIMS\nMETHODS\nRESULTS\nCONCLUSIONS
Turun yliopiston Tutkimustietojärjestelmän portaali